Atezolizumab Monotherapy Beneficial for NSCLC Ineligible for Platinum-Based Chemo
TUESDAY, Aug. 15, 2023 -- For patients with non-small cell lung cancer (NSCLC) ineligible for platinum-based chemotherapy, first-line atezolizumab monotherapy is associated with improved overall survival compared to single-agent chemotherapy,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals